The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.
 
Alexis Ann LeVee
No Relationships to Disclose
 
Colt A. Egelston
Research Funding - Novartis
 
Susan Elaine Yost
No Relationships to Disclose
 
Paul Henry Frankel
Stock and Other Ownership Interests - Asensus Surgical; Geron
Consulting or Advisory Role - Johnson & Johnson/Janssen
 
Keehoon Lee
No Relationships to Disclose
 
Christopher Ruel
No Relationships to Disclose
 
Daniel Schmolze
No Relationships to Disclose
 
Peter P. Lee
No Relationships to Disclose
 
Christina Haeyoung Yeon
No Relationships to Disclose
 
Yuan Yuan
Consulting or Advisory Role - AstraZeneca; Diiachi; Genentech; Merck; Stemline Therapeutics; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Gilead Sciences; Merck
Research Funding - Genentech; Imugene; Merck; Novartis; Pfizer
Expert Testimony - Novartis
 
James Ross Waisman
No Relationships to Disclose
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Joanne E. Mortimer
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech
Research Funding - AstraZeneca